Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Aeglea BioTherapeutics

Reata Pharmaceuticals

At least one of the three could be in store for better news in the future.

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

Why Bolt Biotherapeutics Stock Crashed Today

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR7/8 agonist.

Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated to a TLR7/8 agonist with a non-cleavable linker.

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the company will be presenting posters with new data from three of its pipeline programs on Saturday, Nov. 13, at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held virtually and in person in Washington, D.C. from Nov. 10-14. Each presentation highlights the progress made in preclinical studies to demonstrate the potential for each pipeline candidate as a novel approach for the treatment for cancer.

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 –Strong cash position of $295.5 million expected to fund operations through the end of 2023

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

Three SITC presentations highlight the breadth of immuno-oncology strategies from the company's expanding portfolio Three SITC presentations highlight the breadth of immuno-oncology strategies from the company's expanding portfolio

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics' BDC-1001 in combination with Bristol Myers Squibb's PD-1 checkpoint inhibitor Opdivo® (nivolumab). BDC-1001 is a HER2-targeting Boltbody™ immune-stimulating antibody conjugate (ISAC) in development for the treatment of patients with HER2-expressing solid tumors.

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present a corporate update and conduct meetings with the investment community at four upcoming virtual investor conferences in September:

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

SAN FRANCISCO and SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Bolt Biotherapeutics, Inc. ("Bolt") (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. The parties will leverage Innovent's proprietary therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolt's advanced ISAC technology and myeloid biology expertise to create three new cancer treatments with the potential to provide significant benefit to patients.

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, and Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunistic investment.

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

Beam Therapeutics

Genmab - ADR

MacroGenics

Zai Lab Ltd.

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that a poster presentation discussing preliminary data from the Phase 1/2 clinical trial of BDC-1001, Bolt's lead candidate, was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021. The poster is titled “Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.”

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 AM ET.

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

908 Devices

Midwest Holding

NexImmune

Ortho Clinical Diagnostics Holdings

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock, inclusive of the full exercise by the underwriters of their option to purchase 1,725,000 shares of common stock, at a price to the public of $20.00 per share. The shares are listed for trading on The Nasdaq Global Select Market under the ticker symbol “BOLT”.

Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Angion Biomedica

Atotech

Immunocore Holdings

Landos Biopharma

Lucira Health

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.

The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.

REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00 per share. In addition, Bolt has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol "BOLT" on February 5, 2021.

Bolt Biotherapeutics Prices Upsized Initial Public Offering

Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.

Bolt Biotherapeutics Aims For $150 Million U.S. IPO

News for Bolt Biotherapeutics Stock (BOLT)